Charalampos Pontikoglou

List of Publications by Year
in descending order

36 papers	1,190 citations	430843 18 h-index	377849 34 g-index
36 all docs	36 docs citations	36 times ranked	2285 citing authors

#	Article	IF	Citations
1	Increased proportion and altered properties of intermediate monocytes in the peripheral blood of patients with lower risk Myelodysplastic Syndrome. Blood Cells, Molecules, and Diseases, 2021, 86, 102507.	1.4	4
2	Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood, 2021, 138, 1249-1257.	1.4	15
3	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). Blood, 2021, 138, 1535-1535.	1.4	3
4	Osteogenic differentiation of bone marrow mesenchymal stem cells on chitosan/gelatin scaffolds: gene expression profile and mechanical analysis. Biomedical Materials (Bristol), 2020, 15, 064101.	3.3	10
5	Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells. Leukemia and Lymphoma, 2019, 60, 538-540.	1.3	2
6	Using Electronic Patient Reported Outcomes to Foster Palliative Cancer Care: The MyPal Approach. , 2019, , .		8
7	Myeloidâ€Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. HemaSphere, 2019, 3, e168.	2.7	41
8	Chitosan/gelatin scaffolds support bone regeneration. Journal of Materials Science: Materials in Medicine, 2018, 29, 59.	3.6	56
9	Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Whartonâ€™s jelly and bone marrow-derived mesenchymal stem cells. Stem Cell Research and Therapy, 2017, 8, 102.	5.5	62
10	Immunoglobulin and B-cell disturbances in patients with chronic idiopathic neutropenia. Clinical Immunology, 2017, 183, 75-81.	3.2	2
11	Recombinant human bone morphogenetic protein 2 (rhBMP-2) immobilized on laser-fabricated 3D scaffolds enhance osteogenesis. Colloids and Surfaces B: Biointerfaces, 2017, 149, 233-242.	5.0	32
12	CD200 expression in human cultured bone marrow mesenchymal stem cells is induced by proâ€osteogenic and proâ€inflammatory cues. Journal of Cellular and Molecular Medicine, 2016, 20, 655-665.	3.6	37
13	Endothelial progenitor cells as markers of severity in hypertrophic cardiomyopathy. European Journal of Heart Failure, 2016, 18, 179-184.	7.1	6
14	High Frequency of Thyroid Disorders in Patients Presenting With Neutropenia to an Outpatient Hematology Clinic STROBE-Compliant Article. Medicine (United States), 2015, 94, e886.	1.0	17
15	Adhesion and growth of human bone marrow mesenchymal stem cells on precise-geometry 3D organicâ€“inorganic composite scaffolds for bone repair. Materials Science and Engineering C, 2015, 48, 301-309.	7.3	45
16	Circulating Endothelial Progenitor Cells in Hypertensive Patients With Increased Arterial Stiffness. Journal of Clinical Hypertension, 2014, 16, 295-300.	2.0	16
17	Increased Mobilization of Mesenchymal Stem Cells in Patients With Essential Hypertension: The Effect of Left Ventricular Hypertrophy. Journal of Clinical Hypertension, 2014, 16, 883-888.	2.0	10
18	Wharton's Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (ε-caprolactone) Copolymer for Myocardium Tissue Engineering. Current Pharmaceutical Design, 2014, 20, 2030-2039.	1.9	13

#	Article	IF	Citations
19	Study of the Quantitative, Functional, Cytogenetic, and Immunoregulatory Properties of Bone Marrow Mesenchymal Stem Cells in Patients with B-Cell Chronic Lymphocytic Leukemia. Stem Cells and Development, 2013, 22, 1329-1341.	2.1	27
20	CD200R/CD200 Inhibits Osteoclastogenesis: New Mechanism of Osteoclast Control by Mesenchymal Stem Cells in Human. PLoS ONE, 2013, 8, e72831.	2.5	33
21	Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes. Clinical and Developmental Immunology, 2013, 2013, 1-10.	3.3	22
22	Mesenchymal Stem Cells Derived from Wharton's Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications. Current Stem Cell Research and Therapy, 2013, 8, 144-155.	1.3	192
23	Lymphopenia in patients with chronic idiopathic neutropenia is associated with decreased number of Tâ€lymphocytes containing Tâ€cell receptor excision circles. European Journal of Haematology, 2012, 88, 210-223.	2.2	2
24	Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation. Stem Cell Reviews and Reports, 2011, 7, 569-589.	5.6	160
25	Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor-Î²1. Stem Cells and Development, 2011, 20, 1309-1318.	2.1	19
26	Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes. Current Stem Cell Research and Therapy, 2011, 6, 122-130.	1.3	20
27	Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. Expert Review of Hematology, 2011, 4, 317-328.	2.2	18
28	Bone regeneration: the stem/progenitor cells point of view. Journal of Cellular and Molecular Medicine, 2010, 14, 103-115.	3.6	50
29	Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes. Stem Cells and Development, 2010, 19, 1043-1054.	2.1	63
30	The â^'509C/T polymorphism of transforming growth factorâ€Î²1 is associated with increased risk for development of chronic idiopathic neutropenia. European Journal of Haematology, 2009, 83, 535-540.	2.2	8
31	Specific Lineage-Priming of Bone Marrow Mesenchymal Stem Cells Provides the Molecular Framework for Their Plasticity. Stem Cells, 2009, 27, 1142-1151.	3.2	110
32	Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert Review of Hematology, 2008, 1, 217-229.	2.2	26
33	Human bone marrow native mesenchymal stem cells. Regenerative Medicine, 2008, 3, 731-741.	1.7	39
34	Increased levels of soluble flt-3 ligand in serum and long-term bone marrow culture supernatants in patients with chronic idiopathic neutropenia. British Journal of Haematology, 2006, 132, 637-639.	2.5	5
35	Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia. Annals of Hematology, 2006, 85, 170-173.	1.8	2
36	Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. Experimental Hematology, 2006, 34, 1312-1322.	0.4	15